ORGO vs SRZN
ORGO: Organogenesis is a tissue-engineered wound care and surgical reconstruction company whose financial health depends critically on Medicare reimbursement rates and FDA regulatory compliance. SRZN: Surrozen is a clinical-stage biotechnology company developing regenerative therapies that harness the body's Wnt signaling pathway to repair tissue damage.
Side-by-side fundamentals
| Metric | ORGO | SRZN | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $2.55 | $19.81 | |
| Market cap as of 2026-07-30 | $328M | $230M | |
| P/E as of 2026-07-30 | 119.49 | n/a | |
| PEG as of 2026-07-30 | -2.48 | -0.01 | ORGO lower |
| Net margin as of 2026-07-30 | +0.5% | -4571.1% | ORGO higher |
| Gross margin as of 2026-07-30 | +72.9% | n/a | |
| Operating margin as of 2026-07-30 | +0.5% | -573.8% | ORGO higher |
| ROE as of 2026-07-30 | +0.7% | +58.2% | SRZN higher |
| ROA as of 2026-07-30 | +0.5% | -329.3% | ORGO higher |
| Debt / equity as of 2026-07-30 | 0.03 | 0.00 | SRZN lower |
| Revenue growth (YoY) as of 2026-07-30 | +12.2% | -35.6% | ORGO higher |
| Revenue CAGR (3y) SEC XBRL | +7.8% | n/a | |
| Beta as of 2026-07-30 | 1.34 | 0.58 | |
| 1-year return as of 2026-07-27 close | -49.3% | +121.3% | SRZN higher |
Fundamentals: market data, as of 2026-07-30. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.